Condition
Immune Surveillance
Total Trials
7
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
7Total
Not Applicable (7)
Trial Status
Recruiting3
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07142720Not ApplicableCompletedPrimary
Rapid Effects on Antioxidant Status, Immune Alertness, and Regenerative Activity
NCT07206407Not ApplicableRecruitingPrimary
Clinical Trial on Rapid Immune Modulating Effects
NCT07195552Not ApplicableRecruitingPrimary
Clinical Trial: Rapid Immune Modulating Effects
NCT06754228Not ApplicableRecruitingPrimary
Acute Immune Modulation by Probiotic Strain
NCT05819424Not ApplicableCompletedPrimary
EpiCor Clinical Study on Rapid Immune Modulating Effects
NCT05431751Not ApplicableUnknownPrimary
Clinical Proof-of-concept Study on Immune Surveillance and Alertness
NCT05364710Not ApplicableUnknownPrimary
Clinical Proof-of-concept Study on Rapid Immune Modulating Effects
Showing all 7 trials